» Articles » PMID: 15734840

The Endoplasmic Reticulum Chaperone Improves Insulin Resistance in Type 2 Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 2005 Mar 1
PMID 15734840
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

To determine the role of the endoplasmic reticulum (ER) in diabetes, Akita mice, a mouse model of type 2 diabetes, were mated with either heterozygous knockout mice or two types of transgenic mice of 150-kDa oxygen-regulated protein (ORP150), a molecular chaperone located in the ER. Systemic expression of ORP150 in Akita mice improves insulin intolerance, whereas the exclusive overexpression of ORP150 in pancreatic beta-cells of Akita mice did not change their glucose tolerance. Both an insulin tolerance test and hyperinsulinemic-euglycemic clamp revealed that ORP150 enhanced glucose uptake, accompanied by suppression of oxidized protein. Furthermore, ORP150 enhanced the insulin sensitivity of myoblast cells treated with hydrogen peroxide. These data suggest that ORP150 plays an important role in insulin sensitivity and is a potential target for the treatment of diabetes.

Citing Articles

Endoplasmic Reticulum Stress and Obesity.

Yilmaz E Adv Exp Med Biol. 2024; 1460:373-390.

PMID: 39287859 DOI: 10.1007/978-3-031-63657-8_13.


Obesity disrupts the pituitary-hepatic UPR communication leading to NAFLD progression.

Qian Q, Li M, Zhang Z, Davis S, Rahmouni K, Norris A Cell Metab. 2024; 36(7):1550-1565.e9.

PMID: 38718793 PMC: 11222033. DOI: 10.1016/j.cmet.2024.04.014.


The Role of Obesity in Type 2 Diabetes Mellitus-An Overview.

Chandrasekaran P, Weiskirchen R Int J Mol Sci. 2024; 25(3).

PMID: 38339160 PMC: 10855901. DOI: 10.3390/ijms25031882.


Prospects of potential adipokines as therapeutic agents in obesity-linked atherogenic dyslipidemia and insulin resistance.

Roy P, Islam J, Lalhlenmawia H Egypt Heart J. 2023; 75(1):24.

PMID: 37014444 PMC: 10073393. DOI: 10.1186/s43044-023-00352-7.


Epigenetics and endoplasmic reticulum in podocytopathy during diabetic nephropathy progression.

Wang X, Zhao J, Li Y, Rao J, Xu G Front Immunol. 2023; 13:1090989.

PMID: 36618403 PMC: 9813850. DOI: 10.3389/fimmu.2022.1090989.